The FDA has approved the subcutaneously injected monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.¹

中文翻译：

---

Dupilumab（Dupixent）治疗哮喘

FDA已批准皮下注射单克隆抗体dupilumab（Dupixent – Sanofi / Regeneron）用于对患有嗜酸性表型或口服皮质类固醇依赖性哮喘的中度至重度哮喘≥12岁的患者进行补充维持治疗。Dupilumab较早被批准用于治疗中度至重度特应性皮炎的成人，这些患者在局部疗法的控制下不够充分。^1个